Rocket Pharmaceuticals Inc
RCKT3.170USD
+0.140+4.62%
收盘 09/18, 16:00（美东）报价延迟15分钟
341.99M总市值
亏损市盈率 TTM
关于 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的后期生物技术公司。该公司正在推进一系列可持续的试验性基因疗法，旨在纠正复杂和罕见疾病的根本原因。其基于慢病毒 (LV) 载体的基因疗法针对血液病，包括针对范康尼贫血症（一种难以治疗的遗传病，会导致骨髓衰竭和潜在的癌症）、白细胞粘附缺陷-I (LAD-I)（一种严重的儿科遗传病，会导致反复发作且危及生命的感染，这些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一种单基因红细胞疾病，导致红细胞破坏增加和轻度至危及生命的贫血）的后期项目。该公司还有两个临床阶段和一个临床前阶段的体内腺相关病毒 (AAV) 项目，包括针对 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 扩张型心肌病的项目。
公司简介
公司代码RCKT
公司名称Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
员工数量299
证券类型Ordinary Share
年结日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编08512
电话16464409100
网址https://www.rocketpharma.com/
公司代码RCKT
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
89.74K
+80.42%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Independent Director
Independent Director
40.00K
+33.33%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
30.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
89.74K
+80.42%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月24日 周日
更新时间: 8月24日 周日
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.65%
Suvretta Capital Management, LLC
3.84%
其他
60.48%
持股股东
持股股东
占比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.65%
Suvretta Capital Management, LLC
3.84%
其他
60.48%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
29.71%
Hedge Fund
28.47%
Investment Advisor
24.34%
Research Firm
6.16%
Individual Investor
3.46%
Bank and Trust
0.28%
Pension Fund
0.19%
Venture Capital
0.14%
Family Office
0.04%
其他
7.23%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
493
101.52M
94.23%
-15.02M
2025Q1
494
114.28M
106.44%
-9.69M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
2023Q1
419
83.81M
105.83%
-4.94M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
17.69M
16.42%
--
--
Mar 31, 2025
Maverick Capital, Ltd.
5.55M
5.15%
+347.96K
+6.69%
Apr 07, 2025
BlackRock Institutional Trust Company, N.A.
6.15M
5.71%
+514.15K
+9.13%
Mar 31, 2025
The Vanguard Group, Inc.
6.60M
6.13%
+40.19K
+0.61%
Mar 31, 2025
Suvretta Capital Management, LLC
3.50M
3.25%
+935.05K
+36.43%
Mar 31, 2025
MPM BioImpact LLC
1.62M
1.5%
+597.71K
+58.57%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.99M
1.85%
+241.07K
+13.75%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.78M
1.65%
+991.88K
+125.66%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
